Compugen Advances COM503 to Phase 1 Clinical Trial in Cancer Treatment

Compugen ( (CGEN) ) has provided an announcement.

Compugen has initiated a Phase 1 clinical trial for COM503, a novel anti-IL-18 binding protein antibody, marking a significant advancement in cancer therapeutics. This trial, conducted in collaboration with Gilead Sciences, aims to assess the safety and efficacy of COM503 both as a monotherapy and in combination with zimberelimab in patients with advanced solid tumors. The trial is part of a larger agreement with Gilead, under which Compugen is responsible for the trial phase while Gilead will develop and commercialize the drug. The partnership, valued at up to $848 million, highlights the potential impact of COM503 on cancer treatment and Compugen’s strategic position in the oncology sector.

More about Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery platform, Unigen, to identify new drug targets and biological pathways for developing cancer immunotherapies. The company has several proprietary product candidates in development, including COM701, COM902, and COM503, which are focused on treating solid tumors. Compugen is headquartered in Israel with offices in San Francisco, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

YTD Price Performance: -3.03%

Average Trading Volume: 360,140

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $143.3M

See more data about CGEN stock on TipRanks’ Stock Analysis page.